Clinical LC-MS/MS is one of the fastest-growing segments of analytical science, and AI is now touching nearly every stage of the diagnostics built on it. Machine learning models are flagging abnormal newborn screening profiles, refining therapeutic drug monitoring (TDM) interpretation, and helping toxicologists classify unknown compounds faster than manual review allows. None of these applications replace the clinical laboratory scientist's judgment; each one compresses the time between an LC-MS/MS run and a defensible, reportable result.
Key Takeaways
- A random forest classifier reduced false-positive newborn screening results for several inborn errors of metabolism by wide margins without any loss of sensitivity.
- Deep learning systems built around automated peak recognition are reaching identification accuracies above 98% in early TDM validation studies.
- Forensic and clinical toxicology laboratories are training machine learning classifiers to flag unknown compounds from HRMS spectra that have no matching library entry.
- The FDA's clinical decision support software guidance requires that AI-assisted interpretation tools support, rather than replace, independent clinician review of the underlying data.
- Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) accreditation requirements apply to AI-assisted LC-MS/MS workflows the same way they apply to any other validated laboratory method.
AI and Clinical Chromatography: What Sets This LC-MS/MS Work Apart
Clinical LC-MS/MS analysis differs from other separation science applications because the specimen matrix, turnaround expectations, and downstream clinical consequence of an error are all more constrained than in a research or industrial laboratory. A misclassified peak in a discovery metabolomics run costs a reinjection; a misclassified peak in a therapeutic drug monitoring assay can change a dosing decision, and a missed flag in a toxicology screen can delay a diagnosis with immediate consequences for patient care.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
That difference in consequence is a large part of why clinical laboratories have been comparatively cautious about deploying AI models directly into diagnostic interpretation, even as broader analytical AI adoption across research and industrial laboratories has moved faster. Machine learning is nonetheless entering clinical LC-MS/MS work in specific, bounded roles rather than as a wholesale replacement for manual review.
Retention time prediction, automated flagging of atypical chromatograms, and pattern recognition across large drug or metabolite panels are the areas where models are proving useful without displacing the toxicologist or clinical chemist who signs out the result. Each of these applications is discussed in more detail in the sections that follow, along with the regulatory obligations that come with deploying them in an accredited laboratory.
The table below summarizes how AI-assisted review compares with manual practice across the three clinical LC-MS/MS applications covered in this guide.
| Clinical application | Manual practice | AI-assisted role |
|---|---|---|
| Newborn screening interpretation | Fixed cutoff values applied to each analyte independently | Multi-analyte pattern classification that lowers false-positive triage volume |
| Therapeutic drug monitoring | Analyst manually confirms retention time and peak shape for each new drug | Predictive models estimate retention behavior before injection, speeding method development |
| Unknown compound screening in toxicology | Spectral library matching only; unmatched compounds return no result | Classification models group unmatched spectra with known drug classes for analyst review |
AI-Assisted Newborn Screening Data Review With LC-MS/MS
Tandem mass spectrometry newborn screening generates a metabolite profile for every infant tested, and screening panels are intentionally tuned for high sensitivity, which produces a predictable volume of false-positive results that trigger unnecessary follow-up testing and parental anxiety. A random forest newborn screening model trained on metabolite data from a California screening cohort cut false-positive rates by 89% for glutaric acidemia type 1, 45% for methylmalonic acidemia, and 98% for ornithine transcarbamylase deficiency, with sensitivity for confirmed cases unchanged from the existing cutoff-based approach.
The model works by weighing all measured metabolites and their ratios together rather than applying a fixed cutoff to each analyte independently, which is closer to how an experienced reviewer already reads a complex profile but faster and more consistent across shifts and reviewers. Some laboratories are pairing these classifiers with existing interpretive tools rather than replacing them outright.
A triage layer of this kind does not make a diagnosis; it narrows which abnormal profiles a laboratory director reviews first, which matters when screening volumes run into the hundreds of thousands of specimens a year without a matching increase in review staff. The remaining manual review still confirms every case before any result reaches a pediatrician or family.
AI and Therapeutic Drug Monitoring: Changing LC-MS/MS Interpretation
Therapeutic drug monitoring by LC-MS/MS depends on rapid, accurate peak identification across drug panels that grow every time a new oral or biologic therapy enters routine clinical use, and manual method development struggles to keep pace with that expansion. A deep learning drug monitoring system built around an automated peak-recognition algorithm achieved better than 98% identification accuracy for a panel of psychoactive therapeutic drugs, with quantitative results correlating above 0.99 against conventional LC-MS/MS confirmation across medically relevant concentration ranges.
That level of concordance supports using an AI-assisted system as a faster frontline screen while conventional LC-MS/MS remains the confirmatory method for regulatory and clinical reporting, rather than as a standalone diagnostic tool. The distinction matters for how a laboratory documents its workflow and for which result ultimately appears on a patient's chart.
The same automation pressure shows up earlier in the workflow, in method development rather than in patient-facing interpretation. Supervised machine learning models, including regression-based approaches and artificial neural networks, are being used to predict retention time across large panels of structurally similar drugs, including oral antitumor agents and their active metabolites, compressing the assay development timeline needed to keep pace with new oncology and immunosuppressant therapies entering TDM panels.
Clinical Toxicology and AI-Assisted Compound Screening by LC-MS/MS
Untargeted toxicology screening by HRMS increasingly confronts novel psychoactive substances and designer drugs with no entry in a reference spectral library, which is precisely the scenario where classical library matching fails outright. A forensic toxicology machine learning review groups current approaches into spectra-to-compound, compound-to-spectra, and classification models, and identifies limited training data, polysubstance use, and validation as the practical challenges still facing the field.
Machine learning contributions to toxicology screening cluster around three tasks:
- Classifying an unmatched spectrum as chemically related to a known drug class based on shared fragmentation behavior
- Ranking candidate structures for an analyst to evaluate against authentic reference standards
- Flagging polysubstance patterns across a specimen that a single-analyte screen would likely miss
These classification tools are framed explicitly as triage aids rather than confirmatory identification, which mirrors how the same class of models is used in newborn screening and TDM. A toxicologist still confirms any flagged compound against an authentic reference standard before it appears in a clinical or forensic report, and no classification score substitutes for that confirmatory step.
The broader shift toward machine learning in mass spectrometry data analysis is what makes this kind of classification possible at all: mass spectra are notoriously difficult to represent in a form suited to machine learning, and progress on that representation problem is what is turning unknown-compound classification into a practical laboratory tool rather than a research curiosity.
Integrating AI and LC-MS Data Into Clinical Decision Support
When AI-assisted flags, classifications, or predictions generated from LC-MS/MS data feed into a decision support interface used by a treating clinician, that software function falls under the FDA clinical decision support framework, which requires that a health care professional be able to independently review the basis for any recommendation the software presents rather than rely on it outright. Software intended for time-critical decisions generally does not qualify for that exclusion and instead remains subject to the FDA's standard device requirements.
Laboratory accreditation adds a second layer of oversight that applies regardless of how a result was generated. The CLIA laboratory certification program, administered by the Centers for Medicare & Medicaid Services, and CAP accreditation checklists both require that any analytical method, including one with a machine learning component, be validated for accuracy, precision, and reportable range before it generates a patient result. Neither framework treats an AI-assisted step differently from a conventional calibration curve; the validation burden simply shifts to demonstrating that the model performs consistently on the laboratory's own specimen population rather than only on a vendor's training data.
A laboratory bringing an AI-assisted screening or classification tool into a CLIA- or CAP-accredited workflow typically works through the same sequence used for any new analytical component:
- Validate the model's output against a defined confirmatory method using the laboratory's own specimen population, not vendor-supplied validation data alone.
- Set a documented confidence threshold that distinguishes a flagged result from one requiring no further review.
- Confirm that a laboratory director can independently review the basis for any AI-generated flag before it influences a reported result.
- Establish change-control procedures for the periods when the underlying model is retrained or updated.
AI Is Narrowing Review Time in Clinical LC-MS/MS Diagnostics
Across newborn screening, TDM, and toxicology, AI-assisted tools are converging on the same practical role: they narrow a large candidate list or flag an unusual result faster than manual review alone, without taking over the interpretive judgment that a clinical laboratory scientist or toxicologist is trained and accredited to provide. These three applications sit alongside metabolomics, food safety testing, and environmental analysis as emerging separation science applications where AI is being asked to do real diagnostic and analytical work rather than simply accelerate an existing method. That framing, rather than any promise of autonomous diagnosis, is what is actually reaching clinical LC-MS/MS laboratories today.
The laboratories getting genuine value from these tools are treating them as a triage layer sitting in front of an already-validated method, not as a replacement for it. As drug panels expand and screening volumes grow, that triage function is likely to become a standard feature of clinical mass spectrometry software rather than a specialized add-on, provided the underlying models remain subject to the same validation obligations as every other part of the analytical method.
This article was produced under Separation Science's AI Editorial Guidelines.
